The article offers news briefs in the pharmaceutical industry worldwide in 2006. Merck KgaA's anticancer drug Erbitux has been approved to be used in the expanded indication of head and neck cancer by the regulators of the European Commission. The U.S. Food and Drugs Administration has granted orphan drug designation to Cephalon Inc.'s oncology product candidate lestaurtinib for the treatment of acute myeloid leukemia.
Processing Request
No Comments.